Skoulidis et al. [21] reported that patients with KRAS mutations and STK11/LKB1 alterations had reduced efficacy to immunotherapy in a cohort of 165 patients diagnosed with KRAS-mutated lung adenocarcinoma who had received PD-1/PD-L1 inhibitors treatment. This evidence concerns the gene KRAS and lung adenocarcinoma.